PEG rhG-CSF与rhG-CSF预防恶性肿瘤化疗后中性粒细胞减少的临床疗效及安全性比较

Comparison of clinical efficacy and safety of PEG rhG-CSF and rhG-CSF in preventing neutropenia after chemotherapy for malignant tumors

目的 探究重组人粒细胞集落刺激因子(rhG-CSF)、聚乙二醇化重组人粒细胞刺激因子(PEG rhG-CSF)预防恶性肿瘤化疗后中性粒细胞减少的疗效及安全性。方法 选取60例恶性肿瘤化疗患者作为研究对象,采用自身对照实验,第1次化疗结束24 h后给予患者rhG-CSF治疗作为对照组;第2次化疗结束24 h后给予患者PEG rhG-CSF治疗作为试验组。比较两组用药后出现严重骨髓抑制(Ⅲ~Ⅳ度)情况、出现严重骨髓抑制(Ⅲ~Ⅳ度)患者外周血中性粒细胞绝对值(ANC)恢复时间、治疗期间不良反应发生情况及患者生活质量评分。结果 试验组用药后出现严重中性粒细胞减少(Ⅲ度和Ⅳ度)发生率为11.67%,少于对照组的23.33%,差异有统计学意义(P<0.05)。试验组出现严重骨髓抑制(Ⅲ度和Ⅳ度)患者ANC恢复时间为(2.69±0.74)d,短于对照组的(4.16±1.38)d,差异有统计学意义(P<0.05)。两组总不良反应发生率比较差异无统计学意义(P>0.05)。治疗后,两组EORTC生命质量测定量表(QLQ-C30)评分均低于本组治疗前,且试验组QLQ-C30评分为(36.34±4.11)分,低于对照组的(45.63±6.11)分,差异有统计学意义(P<0.05)。结论 PEG rhG-CSF能更好地预防恶性肿瘤化疗后出现的中性粒细胞减少并发症,值得临床推广。

Objective To investigate the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor(PEG rhG-CSF) and recombinant human granulocyte colony-stimulating factor(rhG-CSF) in preventing neutropenia after chemotherapy for malignant tumors.Methods 60 patients with chemotherapy for malignant tumors were selected as the study subjects,and a self-controlled experiment was conducted,in which patients receiving rhG-CSF treatment 24 h after the end of the 1st chemotherapy were taken as the control group;patients receiving PEG rhG-CSF treatment 24 h after the end of the 2nd chemotherapy were taken as the experimental group.Both groups were compared in terms of occurrence of severe myelosuppression(Ⅲ-Ⅳ degree) after medication,recovery time of absolute neutrophil count(ANC) in patients with severe myelosuppression(Ⅲ-Ⅳ degree),occurrence of adverse reactions during treatment,and quality of life score.Results The incidence of severe myelosuppression(Ⅲ-Ⅳ degree) after medication in the experimental group was 11.67%,which was less than 23.33% in the control group,and the difference was statistically significant(P0.05).After treatment,the Quality of Life Questionnaire C30(QLQ-C30) scores in both groups were lower than those before treatment in this group,and the QLQ-C30 score in the experimental group was(36.34±4.11) points,which was lower than(45.63±6.11) points in the control group,and the differences were statistically significant(P<0.05).Conclusion PEG rhG-CSF can better prevent neutropenia that occur after chemotherapy for malignant tumors and is worthy of clinical promotion.